Disclosure by Pfizer Clause Samples

Disclosure by Pfizer. In the interest of transparency relating to its relationships with investigators and study sites or to ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides under this Agreement. Such a disclosure by Pfizer may identify both the Institution and the Principal Investigator, but will clearly differentiate between payments or other transfers of value to institutions and those made to individuals.
View SourceView Similar (19)
Disclosure by Pfizer. In the interest of transparency relating to its financial relationships with investigators and study sites or to ensure compliance with Applicable Law, industry codes and Pfizer policies, Pfizer may, and (in certain cases) is required to, report or otherwise disclose publicly payments or other transfer of value to certain health care providers, teaching hospitals and other health care organizations, including Funding provided under this Agreement. These laws and codes, and their implementing regulations, collectively are referred to as “Transparency Obligations.” Pfizer may disclose in any lawful manner the terms of this Agreement and any other information to the extent necessary for Pfizer to meet its Transparency Obligations. The terms of the Agreement shall be publicly disclosed on Pfizer’s webpage (▇▇▇.▇▇▇▇▇▇.▇▇) when the Agreement is made and for a period of 2 years thereafter.
View SourceView Similar (2)
Disclosure by Pfizer. In the interest of transparency relating to its financial relationships with investigators and Study/Registry sites or to ensure compliance with Applicable Law, industry codes and Pfizer policies, Pfizer may, and (in certain cases) is required to, report or otherwise disclose publicly payments or other transfer of value to certain health care providers, teaching hospitals and other health care organizations, including Funding provided under this Agreement. These laws and codes, and their implementing regulations, collectively are referred to as “Transparency Obligations.” Pfizer may disclose in any lawful manner the terms of this Agreement poskytovaných státem. 3.5 Žádné platby účtované třetím osobám. Příjemce grantu zajistí, aby žádnému subjektu studie, pojišťovně, orgánu veřejné moci ani jinému plátci ze strany třetích osob nebyly účtovány žádné platby za jakékoli činnosti související se Studií/Registrem prováděné Příjemcem grantu za použití Financování. 3.6
View Source
Disclosure by Pfizer. In the interest of transparency relating to its relationships with investigators and study sites or to 2.2 Zverejnenie informácií zo strany spoločnosti Pfizer. V záujme transparentnosti ohľadom jej vzťahu so ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides under this Agreement. Such a disclosure by Pfizer may identify both the Institution and the Principal Investigator, but will clearly differentiate between payments or other transfers of value to institutions and those made to individuals. skúšajúcimi a pracoviskami klinického skúšania, alebo aby sa zabezpečilo dodržiavanie príslušných právnych predpisov môže spoločnosť Pfizer zverejniť podporu, ktorú poskytuje v rámci tejto zmluvy. Takéto zverejnenie informácií zo strany spoločnosti Pfizer môže identifikovať inštitúciu aj hlavného skúšajúceho, ale jasne rozlíši medzi platbami alebo inými prevodmi hodnôt inštitúcii a jednotlivcom.
View Source
Disclosure by Pfizer. Subcontractor acknowledges that Pfizer is subject to laws related to the collection and reporting of any payments or transfers of value to certain healthcare professionals and teaching hospitals (hereinafter: the “Payments to Healthcare Professionals”), including those laws, industry codes and accompanying implementing regulations, including section 6002 of the Affordable Care Act and The European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on Disclosure of Transfers of Value (hereinafter, collectively, the “Transparency Laws”). Pfizer may disclose in any lawful manner the terms of Master Agreement and SOW, the support that Pfizer is providing under it, and any other information to the extent necessary for Pfizer to meet its obligations under the Transparency Laws including certain identifying information of healthcare professionals including names, National Provider Identifier, licensure number(s), specialty, and addresses. Subcontractor will provide Penta and/or Pfizer with all information Pfizer needs to meet its obligations under any Transparency Laws including identifying healthcare professionals and teaching hospitals that receive a payment or transfer-of- value stemming from Pfizer’s support under the Master Agreement and SOW, as well as the amounts and dates of those payments or transfers-of-value. In accordance with EFPIA Disclosure Code and local country privacy and legal requirements, a signed consent document may be collected. Subcontractor will provide the information required under this paragraph by accurately completing a data report in a format reasonably determined by Pfizer.
View Source
Disclosure by Pfizer. In the interest of transparency relating to its financial relationships with investigators and study sites or to ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides under this Agreement. Institution agrees that Pfizer may disclose in any lawful manner the terms of this Agreement, the support or funding that Pfizer is providing under this Agreement, and any other related information, to the extent necessary for Pfizer to meet its obligations under those laws, regulations and industry codes that require Pfizer to report payments or other transfers of value to certain healthcare professionals and teaching hospitals (collectively, the “Transparency Laws”). Transparency Laws include, without limitation, section 6002 of the U.S. Affordable Care Act and the EFPIA Code on Disclosure of Transfers of Value.
View Source
Disclosure by Pfizer. In the interest of transparency relating to its relationships with investigators and study sites or to ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides under this Agreement. Such a disclosure by Pfizer may identify both the Health Services Provider and the Principal Investigator, but will clearly differentiate between payments or other transfers of value to legal persons and those made to individuals. Z veřejnění informací společností Pfizer. V zájmu transparence svých finančních vztahů se zkoušejícími a studijními pracovišti, nebo z důvodu zajištění dodržování příslušných místních právních předpisů, může společnost Pfizer zveřejnit finanční odměnu, kterou podle této Smlouvy poskytuje. Takové zveřejnění společností Pfizer může identifikovat jak Poskytovatele zdravotních služeb, tak i Hlavního zkoušejícího, ale bude zřetelně rozlišovat mezi platbami a jinými převody hodnot, jež jsou poukázány právnickým osobám, a těmi, jež jsou poukázány jednotlivcům.
View Source
Disclosure by Pfizer. In the interest of transparency relating to its relationships with 2.2
View Source

Related to Disclosure by Pfizer

  • NEPOTISM DISCLOSURE A. In this section the term “relative” means: (1) a person's great grandparent, grandparent, parent, aunt or uncle, sibling, niece or nephew, spouse, child, grandchild, or great grandchild, or (2) the grandparent, parent, sibling, child, or grandchild of the person’s spouse. B. A notification required by this section shall be submitted in writing to the person designated to receive official notices under this contract and by first-class mail addressed to Contract Services, Texas Department of Transportation, ▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇. The notice shall specify the Engineer's firm name, the name of the person who submitted the notification, the contract number, the district, division, or office of TxDOT that is principally responsible for the contract, the name of the relevant Engineer employee, the expected role of the Engineer employee on the project, the name of the TxDOT employee who is a relative of the Engineer employee, the title of the TxDOT employee, the work location of the TxDOT employee, and the nature of the relationship. C. By executing this contract, the Engineer is certifying that the Engineer does not have any knowledge that any of its employees or of any employees of a subcontractor who are expected to work under this contract have a relative that is employed by TxDOT unless the Engineer has notified TxDOT of each instance as required by subsection (b). D. If the Engineer learns at any time that any of its employees or that any of the employees of a subcontractor who are performing work under this contract have a relative who is employed by TxDOT, the Engineer shall notify TxDOT under subsection (b) of each instance within thirty days of obtaining that knowledge. E. If the Engineer violates this section, TxDOT may terminate the contract immediately for cause, may impose any sanction permitted by law, and may pursue any other remedy permitted by law.

  • Disclosure to FERC its Staff, or a State. Notwithstanding anything in this Article 22 to the contrary, and pursuant to 18 C.F.R. section 1b.20, if FERC or its staff, during the course of an investigation or otherwise, requests information from one of the Parties that is otherwise required to be maintained in confidence pursuant to this Agreement or the NYISO OATT, the Party shall provide the requested information to FERC or its staff, within the time provided for in the request for information. In providing the information to FERC or its staff, the Party must, consistent with 18 C.F.R. section 388.112, request that the information be treated as confidential and non-public by FERC and its staff and that the information be withheld from public disclosure. Parties are prohibited from notifying the other Parties to this Agreement prior to the release of the Confidential Information to the Commission or its staff. The Party shall notify the other Parties to the Agreement when it is notified by FERC or its staff that a request to release Confidential Information has been received by FERC, at which time the Parties may respond before such information would be made public, pursuant to 18 C.F.R. section 388.112. Requests from a state regulatory body conducting a confidential investigation shall be treated in a similar manner if consistent with the applicable state rules and regulations. A Party shall not be liable for any losses, consequential or otherwise, resulting from that Party divulging Confidential Information pursuant to a FERC or state regulatory body request under this paragraph.

  • DISCLOSURE; ACCESS TO INFORMATION The Investor had an opportunity to review copies of the SEC Documents filed on behalf of the Company and has had access to all publicly available information with respect to the Company.

  • Public Information Public Records Disclosure Requests Washington’s Public Records Act. Unless statutorily exempt from public disclosure, this Cooperative Purchasing Agreement and all related records are subject to public disclosure as required by Washington’s Public Records Act, RCW 42.56.

  • Disclosure Updates Promptly and in no event later than 5 Business Days after obtaining knowledge thereof, notify Agent if any written information, exhibit, or report furnished to the Lender Group contained, at the time it was furnished, any untrue statement of a material fact or omitted to state any material fact necessary to make the statements contained therein not misleading in light of the circumstances in which made. The foregoing to the contrary notwithstanding, any notification pursuant to the foregoing provision will not cure or remedy the effect of the prior untrue statement of a material fact or omission of any material fact nor shall any such notification have the effect of amending or modifying this Agreement or any of the Schedules hereto.